Filing excerpt
On September 23, 2026, Bio-Techne issued a press release announcing Bio-Techne shareholders’ approval of the Merger Agreement Proposal.
sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_8k.htmRead the full source
Bio-Techne8-K: Restructuring
Bio-Techne shareholders approve merger with Merck KGaA, triggering a massive post-merger integration initiative.
What happened
The approved merger necessitates the full integration of Bio-Techne's operations into Merck KGaA.
Source
Other signals in this filing (3)
- Acquisition announcedBio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, GermanyAcquisition announced
- Restructuring chargeBio-Techne shareholders approve merger with Merck KGaA, triggering major operational integration.Restructuring charge
- Customer churnBio-Techne flags risk of customer loss and business disruption following merger approval.Customer churn
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Restructuring
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Filed
- Sep 23, 2026
More from Bio-Techne
- PatentsBio-Techne Corporation's patent output is steady: 1 grant in the past year, 0 in the past 30 days.Patents
- 8-KBio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, Germany8-K
- New locationBio-Techne Opens New Customer Experience Centre in Düsseldorf, Strengthening Scientific Exchange and Collaboration with Customers in EuropeNew location
- CertificationBio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate GoalsCertification
- 10-KBio-Techne completed acquisition of spatial biology firm Lunaphore in fiscal 202410-K
- GlassdoorEmployees report lack of growth opportunities and encouragementGlassdoor
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 842023
- Accession number
- 0001140361-26-037450
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Change management needs
- Signal category
- Workforce
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Neutral
- Detected
- Sep 29, 2026
- signal_type
sec-8k- signal_subtype
restructuring
Use this data
Get every 8-K signal for Bio-Techne and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bio-Techne this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/5899521f-52c7-4ad2-8b2b-3438f26a35c1 returns this record as JSON. POST /v1/companies/enrich returns every signal for bio-techne.com.
{
"signal_id": "5899521f-52c7-4ad2-8b2b-3438f26a35c1",
"signal_type": "sec-8k",
"signal_subtype": "restructuring",
"detected_at": "2026-09-29T08:08:49.727+00:00",
"company": {
"name": "Bio-Techne",
"domain": "bio-techne.com"
},
"data": {
"detail": "The approved merger necessitates the full integration of Bio-Techne's operations into Merck KGaA. This creates significant business disruption risks, including challenges in integrating operations, potential customer loss, and difficulties retaining key employees, opening opportunities for vendors specializing in M&A integration, system consolidation, and change management.",
"metrics": {
"timeframe": "immediate"
},
"summary": "Bio-Techne shareholders approve merger with Merck KGaA, triggering a massive post-merger integration initiative.",
"excerpts": "On September 23, 2026, Bio-Techne issued a press release announcing Bio-Techne shareholders’ approval of the Merger Agreement Proposal.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_8k.htm",
"filing_date": "2026-09-23",
"filing_year": 2026,
"sales_relevance": "Change management needs",
"signal_category": "workforce"
}
}
curl https://signals.autobound.ai/v1/signals/5899521f-52c7-4ad2-8b2b-3438f26a35c1 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.